Drugs / [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01479348 | Nov 2011 → Aug 2017 | breast neoplasm, head and neck neoplasm, lung neoplasm, urinary bladder neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]-5-FLUORO-2'-DEOXYCYTIDINE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01479348 ↗ |
| Action | Inhibit | “FdCyd is an inhibitor of deoxyribonucleic acid (DNA) methyltransferase” NCT01479348 ↗ |
| Modality | Diagnostic / imaging agent | “18FdCyd radiotracer” NCT01479348 ↗ |
| Route | Intravenous | “administered intravenously” NCT01479348 ↗ |